Lori A. Leslie, MD, discusses the current treatment options for patients with mantle cell lymphoma.
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the current treatment options for patients with mantle cell lymphoma (MCL).
MCL is a very complicated lymphoma, Leslie says. In the upfront setting, physicians should consider factors like age, comorbidities, and what is driving the lymphoma, such as a P53 abnormality. The treatment options in this setting include high-dose chemotherapy and autologous stem cell transplant.
For patients with MCL who are older and less fit, options include bendamustine/rituximab (Rituxan)-like regimens. In a rare subset of patients with MCL, the watch and wait approach could be appropriate, but this is less common in MCL than in other indolent lymphomas.
Overall, Leslie says that she encourages participation in clinical trials for MCL. There are many ongoing studies right now evaluating novel agents, BTK inhibitors, BCL2 inhibitors, combination regimens, and more.